EUVIMEDEUVIMED entdecken
Randomisierte kontrollierte StudieKlinische Studie (Phase III)

Final overall survival analysis and exploratory biomarker study from JUPITER-06: a randomized phase III trial of toripalimab plus chemotherapy in advanced esophageal squamous-cell carcinoma

Y X Chen, Y Jin, Y K Chen, C Cui, J Yao, Y Zhang, M Li, G Cao, S Yang, Y Fan, J Shi, X Zhang und 13 weitere

Annals of Oncology · 2026-07 · 37 (7) · 986-998

DOI: 10.1016/j.annonc.2026.01.005 ↗

Kurz gefasst

Randomisierte kontrollierte Studie in der Zeitschrift Annals of Oncology, 2026-07. Verfasst von Y X Chen und 24 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medical Oncology, Sun Yat-Sen University Cancer Center, State Key Laboratory of Oncology in South China, Collaborative Innovation Cente…. Hauptthemen laut MEDLINE: Antineoplastic Combined Chemotherapy Protocols, Esophageal Squamous Cell Carcinoma, Biomarkers, Tumor, Esophageal Neoplasms. Die Arbeit wurde bisher 8-mal zitiert (Crossref) und nennt 51 Literaturangaben. Gefördert von: Natural Science Foundation of Guangdong Province, China Postdoctoral Science Foundation, Sun Yat-sen University Cancer Center.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

BACKGROUND: The interim analysis of the JUPITER-06 study reveals significantly longer progression-free survival (PFS) and overall survival (OS) in advanced esophageal squamous-cell carcinoma (ESCC) patients treated with toripalimab in combination with paclitaxel (Taxol) plus cisplatin (TP). Prior work proposed copy number alteration-corrected tumor mutational burden (ccTMB) and an esophageal cancer genome-based immuno-oncology classification (EGIC) scheme as prespecified biomarkers to predict treatment efficacy. Here, we present the final analysis of the JUPITER-06 study and further explore potential biomarkers associated with OS. PATIENTS AND METHODS: A total of 514 patients with treatment-naïve advanced ESCC were randomly assigned 1: 1 to receive toripalimab or placebo in combination with paclitaxel plus cisplatin every 3 weeks for up to six cycles, followed by toripalimab or placebo maintenance. The coprimary endpoints were OS and PFS assessed by blinded independent central review. Whole exome sequencing of 486 tumors enabled biomarker analyses. RESULT: As of 23 February 2023, toripalimab plus TP significantly improved OS versus placebo plus TP [17.7 months, 95% confidence interval (CI) 14.6-20.8 months versus 12.9 months, 95% CI 11.6-14.1 months; hazard ratio (HR) 0.72, 95% CI 0.58-0.88, P = 0.002). The 3-year OS rates were 29.7% and 19.9% in the two groups, respectively. Neither programmed death-ligand 1 (PD-L1) expression nor TMB significantly correlated with OS benefit. In contrast, prespecified biomarkers, ccTMB, and EGIC scheme robustly stratified patients with different long-term OS benefits from immunochemotherapy. Further exploratory analysis discovered that loss-of-function alterations in the SWI/SNF chromatin remodeling complex were associated with improved OS, whereas gain-of-function alterations in cell cycle and WNT signaling pathways correlated with reduced survival benefits. Importantly, CDK4/6 and PORCN inhibitors were identified as potential partners to overcome resistance and enhance the efficacy of immunochemotherapy. CONCLUSION: This final OS analysis of JUPITER-06 confirms the sustained survival benefit of toripalimab plus chemotherapy in advanced ESCC. ccTMB and EGIC enable consistently precise patient stratification, while pathway-specific vulnerabilities highlight actionable targets for exploratory combination strategies.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Antineoplastic Combined Chemotherapy ProtocolsEsophageal Squamous Cell CarcinomaBiomarkers, TumorEsophageal NeoplasmsAntibodies, Monoclonal, HumanizedHumansPaclitaxelFemaleCisplatinMaleMiddle AgedAgedAdultProgression-Free Survival

Stichwörter der Autor:innen

PD-1 inhibitoradvanced esophageal squamous-cell carcinomagenomic biomarkermulti-centerwhole exome sequencing

Substanzen

Biomarkers, TumorPaclitaxelAntibodies, Monoclonal, HumanizedtoripalimabCisplatin

Autor:innen und Institutionen

  • Department of Medical Oncology, Sun Yat-Sen University Cancer Center, State Key Laboratory of Oncology in South China, Collaborative Innovation Center of Cancer Medicine, Guangzhou, China; Research Unit of Precision Dia…
  • Cancer Hospital Chinese Academy of Medical Sciences, Beijing, China.
  • The First Affiliated Hospital of Henan University of Science and Technology, Luoyang, China.
  • Harbin Medical University Cancer Hospital, Harbin, China.
  • Army Medical Center of PLA, Chongqing, China.
  • Jiangsu Cancer Hospital, Nanjing, China.

Förderung

  • Natural Science Foundation of Guangdong Province
  • China Postdoctoral Science Foundation
  • Sun Yat-sen University Cancer Center
  • National Natural Science Foundation of China
  • National Science and Technology Major Project
  • Beijing Xisike Clinical Oncology Research Foundation
  • Ministry of Science and Technology of the People's Republic of China
  • National Science Fund for Distinguished Young Scholars

Zitieren

APA

Chen, Y. X., Jin, Y., Chen, Y. K., Cui, C., Yao, J., Zhang, Y., Li, M., Cao, G., Yang, S., Fan, Y., Shi, J., Zhang, X., Shen, L., Shu, Y., Wang, C., Dai, T., Mao, T., Luo, X., Zhang, X., …, & JUPITER-06 investigators (2026). Final overall survival analysis and exploratory biomarker study from JUPITER-06: a randomized phase III trial of toripalimab plus chemotherapy in advanced esophageal squamous-cell carcinoma. Annals of Oncology, 37(7), 986-998. https://doi.org/10.1016/j.annonc.2026.01.005

Vancouver

Chen YX, Jin Y, Chen YK, Cui C, Yao J, Zhang Y, et al. Final overall survival analysis and exploratory biomarker study from JUPITER-06: a randomized phase III trial of toripalimab plus chemotherapy in advanced esophageal squamous-cell carcinoma. Annals of Oncology. 2026;37(7):986-998. doi:10.1016/j.annonc.2026.01.005

BibTeX
@article{Chen2026,
  author = {Chen, Y X and Jin, Y and Chen, Y K and Cui, C and Yao, J and Zhang, Y and Li, M and Cao, G and Yang, S and Fan, Y and Shi, J and Zhang, X and Shen, L and Shu, Y and Wang, C and Dai, T and Mao, T and Luo, X and Zhang, X and Xie, H and Zou, J and Xu, R H and Wang, Z X and Wang, F and JUPITER-06 investigators, JUPITER-06 investigators},
  title = {Final overall survival analysis and exploratory biomarker study from JUPITER-06: a randomized phase III trial of toripalimab plus chemotherapy in advanced esophageal squamous-cell carcinoma},
  journal = {Annals of Oncology},
  year = {2026},
  volume = {37},
  number = {7},
  pages = {986--998},
  doi = {10.1016/j.annonc.2026.01.005}
}
Kostenlos starten →